Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
How does baricitinib compare in RA patients at risk of VTE?
Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.
How does baricitinib compare in RA patients at risk of VTE?
03 Jul 2026
Novel extended-release tablet superior to febuxostat at reducing SUA levels
An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.
Novel extended-release tablet superior to febuxostat at reducing SUA levels
03 Jul 2026
Rucaparib extends time to subsequent therapy in advanced ovarian cancer
In patients with newly diagnosed advanced ovarian cancer, treatment with rucaparib delays the median time to first and second subsequent anticancer therapy for almost 1 year relative to placebo, according to a study presented at ESMO Gyn 2026.
Rucaparib extends time to subsequent therapy in advanced ovarian cancer
02 Jul 2026
Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer
Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.